Wright Don - 17 Jun 2025 Form 4 Insider Report for International Stem Cell CORP (ISCO)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
20 Jun 2025, 08:21:17 UTC
Prior SEC filing
13 Jun 2024
Next SEC filing
23 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Russell Kern, as Attorney-in-Fact

Key filing fact

Wright Don filed Form 4 for International Stem Cell CORP (ISCO) on 20 Jun 2025.

Key facts

  • This page summarizes Wright Don's Form 4 filing for International Stem Cell CORP (ISCO).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 20 Jun 2025, 08:21.

Change

  • Previous filing in this sequence was filed on 13 Jun 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001405212 Primary reporting owner

Don Wright

Relationship
Director
Address
C/O INTERNATIONAL STEM CELL CORP., 9745 BUSINESSPARK AVENUE, SAN DIEGO
Signature
/s/ Russell Kern, as Attorney-in-Fact
Signature date
19 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ISCO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+30,000
Change %
Price
$0.000000
Shares after
30,000
Date
17 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
30,000
Exercise price
$0.1300
Footnotes
F1
ISCO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
$0
Shares
+532,786
Change %
Price
$0.000000
Shares after
532,786
Date
17 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
532,786
Exercise price
$0.1300
Footnotes
F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares underlying such option shall vest on the earlier of (a) June 17, 2026, or (b) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant.

Footnote F2

The shares underlying such option shall vest in equal quarterly increments through June 17, 2026, with the first increment vesting on September 17, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .